The primary objective is to estimate the relative bioavailability of fixed azithromycin / chloroquine combination tablets relative to co-administered individual tablets of azithromycin and chloroquine.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
40
Pfizer will provide the study medications, fixed combination azithromycin/chloroquine tablets (250 mg/155 mg, base), The study treatment is single dose.
Pfizer will provide Zithromax (500 mg) and Aralen (500 mg containing 300 mg chloroquine base). The study treatment is single dose.
Pfizer Investigational Site
New Haven, Connecticut, United States
AUClast and Cmax of azithromycin and chloroquine for each treatment.
Time frame: up to 96 hours post dose on Day 5
Tmax of azithromycin and chloroquine for each treatment cohort.
Time frame: up to 96 hours post dose on Day 5
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.